Results 61 to 70 of about 1,320,527 (284)

Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines

Biomolecules
Through the mineralocorticoid receptor, aldosterone controls extracellular volume and arterial blood pressure by stimulating Na+ absorption and K+ secretion in epithelial cells of the kidney, colon, and several glands.
Elena Kohm, Martina Feger, Michael Föller   +2 more
doaj   +1 more source

Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Duchenne muscular dystrophy incurs nearly universal dilated cardiomyopathy by the third decade of life, preceded by myocardial damage and impaired left ventricular strain by cardiac magnetic resonance.
Subha V. Raman, Kan N. Hor, Wojciech Mazur, Andrea Cardona, Xin He, Nancy Halnon, Larry Markham, Jonathan H. Soslow, Michael D. Puchalski, Scott R. Auerbach, Uyen Truong, Suzanne Smart, Beth McCarthy, Ibrahim M. Saeed, Jeffrey M. Statland, John T. Kissel, Linda H. Cripe   +16 more
doaj   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease [PDF]

Clinical Journal of the American Society of Nephrology, 2020
Ten years ago, I presented an outline for a study aiming to prevent diabetic kidney disease (DKD), with early intervention in subjects with type 2 diabetes and high risk for DKD assessed by a urinary proteomic–based biomarker, at Kidney Week hoping for positive feedback.
openaire   +3 more sources

Potential target-organ protection of mineralocorticoid receptor antagonist in acute kidney disease

, 2018
[[abstract]]OBJECTIVES: Acute kidney disease (AKD), the transition of acute kidney injury to chronic kidney disease, has major clinical significance. Whether mineralocorticoid receptor antagonist will afford target organ protection during this critical ...
Lin, YF;Chen, L;Lin, SL;Yeh, YC;Huang, TM;Chou, YH;Chang, FC;Chen, YT;Yang, SY;Lai, TS;Wu, VC;Chu, TS;Wu, KD; the National Taiwan University Hospital Study Group on Acute Renal Failure(NSARF) ; Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group
core   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics

Molecules
The mineralocorticoid receptor (MR) is a steroid hormone receptor that plays a key role in regulating sodium and water homeostasis and blood pressure.
Julia J. Liang, Sara Cao, Andrew Hung, Assam El-Osta, Tom C. Karagiannis, Morag J. Young   +5 more
doaj   +1 more source

Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1‐7)/MAS receptor axes in human mesangial cells

Physiological Reports, 2019
The kidney is an important target of the renin‐ANG‐aldosterone system (RAAS). To date, several studies have demonstrated the existence of a local RAAS in various tissues, including the renal tissue.
Danielle Stoll, Rodrigo Yokota, Danielle Sanches Aragão, Dulce E. Casarini   +3 more
doaj   +1 more source

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. [PDF]

PLoS ONE, 2017
The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidney disease.
Jochen Dutzmann, Robert-Jonathan Musmann, Marco Haertlé, Jan-Marcus Daniel, Kristina Sonnenschein, Andreas Schäfer, Peter Kolkhof, Johann Bauersachs, Daniel G Sedding   +8 more
doaj   +1 more source

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone

Circulation Reports, 2021
Background: The effects of mineralocorticoid receptor antagonists, including the newly introduced esaxerenone, on renal function remain uncertain. Methods and Results: This retrospective study was performed on patients who received esaxerenone for resistant hypertension between November 2019 and June 2020.
Oshima, Akira, Imamura, Teruhiko, Narang, Nikhil, Kinugawa, Koichiro   +3 more
openaire   +4 more sources